The independent source for health policy research, polling, and news.
1,221 - 1,240 of 1,288 Results
Medicaid and other health insurers require doctors to file time-consuming paperwork before allowing them to prescribe drugs that help people quit opioids. That delay fosters relapse, specialists say.
A study published in Health Affairs concludes that the idea of coordinating prescription refill timelines for people with multiple chronic conditions could improve their medication adherence and health outcomes.
Most medical schools offer very little education on treating opioid addiction. Stanford University's medical school is trying to ramp it up.
Some experts said the findings stemming from this systematic review of existing studies was reassuring, but not surprising.
Insurance claims for medical services related to opioid dependence diagnoses rose more than 3,000 percent between 2007 and 2014, an analysis finds.
The incidence of opioid use disorder is growing rapidly within the Medicare population.
Federal spending has soared for drugs that are handmade in local pharmacies, and federal investigators are raising concerns about fraud or overbilling.
Researchers found that nearly 15 percent of seniors filled prescriptions for an opioid painkiller after leaving the hospital and of those, 42.5 percent had the order refilled later.
The American Heart Association issues a statement to guide heart failure patients and doctors about the effects that drugs for other conditions can have on the heart.
Mental illness is common — and so are misperceptions about it. These too-often-believed myths can be harmful to you and your loved ones.
Presidential candidates from both parties have proposals they say would help lower the cost of prescription drugs. But most experts say that efforts to regulate prices might not end up saving much money.
Patrick Kennedy, a former congressman from Rhode Island, and Newt Gingrich, who was once the House speaker, are advancing policies to combat this national crisis.
A Health Affairs study determines that Part D spending went down slightly on prescription drugs for which medical marijuana is viewed as a possible alternative.
A study in Health Affairs finds Medicare Part D beneficiaries were charged copays averaging 10.5 times more for Crestor and Nexium than generic drugs would have cost them.
Over the past few months, Massachusetts, Florida, New York, Delaware and Washington have lifted restrictions on the expensive medications, and private insurers around the country are also making the changes.
The case alleges that insured consumers were overcharged because of a contract agreement.
Proposed legislation would require drugmakers to disclose and justify price hikes. The industry has taken to Facebook and Twitter, warning that the proposal could lead to medication shortages in some regions of the state.
Amid growing concern about rising drug costs, the practices of prescription benefit management firms are drawing a new level of attention.
Staff researchers at California’s largest public buyer of health benefits say the goal of reducing drug costs for the state is appealing but might not work in the real world.
The Medicare Payment Advisory Commission outlined a package of changes to Medicare’s drug program that could save billions of dollars.
© 2026 Â鶹ŮÓÅ